Novel therapeutic approaches in limiting oxidative stress and inflammation

Current Pharmaceutical Biotechnology

Volumn 13, Issue 13, 2012, Pages 2456-2466

  Spychalowicz, Agnieszka ^a   Wilk, Grzegorz ^a   Śliwa, Tomasz ^a   Ludew, Dominik ^a   Guzik, Tomasz J ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antioxidants; Inflammation; NADPH oxidases; Nitric oxide; Reactive oxygen species; Superoxide

Indexed keywords

ALLOPURINOL; ANTHOCYANIN; APOCYNIN; ATORVASTATIN; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUINDOSTATIN; GHRELIN; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; LIPOXYGENASE; MANGANESE SUPEROXIDE DISMUTASE; MITOGEN ACTIVATED PROTEIN KINASE; NORPHENAZONE; POLYPHENOL; PR 39; PROTEIN KINASE C; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROSUVASTATIN; RUBOXISTAURIN; SEPIAPTERIN; SIMVASTATIN; SUPEROXIDE; THIOREDOXIN; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADIPOCYTE; APOPTOSIS; ARTICLE; ATHEROGENESIS; BLOOD FLOW; BRAIN BLOOD VESSEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE THERAPY; HUMAN; INFLAMMATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN EXPRESSION; RISK FACTOR; VASOCONSTRICTION;

EID: 84861673228     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201011208062456     Document Type: Article

References (127)

1. Madamanchi, N. R.; Vendrov, A.; Runge, M. S. Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol., 2005, 25(1), 29-38.
2. Harrison, D.; Griendling, K. K.; Landmesser, U.; Hornig, B.; Drexler, H. Role of oxidative stress in atherosclerosis. Am. J. Cardiol., 2003, 91(3A), 7A-11A.
3. Cai, H.; Harrison, D. G. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ. Res., 2000, 87(10), 840-844.
4. Griendling, K. K.; FitzGerald, G. A. Oxidative stress and cardiovascular injury: Part ii: Animal and human studies. Circulation, 2003, 108(17), 2034-2040.
5. Gozin, A.; Franzini, E.; Andrieu, V.; Da Costa, L.; Rollet-Labelle, E.; Pasquier, C. Reactive oxygen species activate focal adhesion kinase, paxillin and p130cas tyrosine phosphorylation in endothelial cells. Free Radic. Biol. Med., 1998, 25(9), 1021-1032.
6. Guzik, T. J.; West, N. E. J.; Black, E.; McDonald, D.; Ratnatunga, C.; Pillai, R.; Channon, K. M. Vascular superoxide production by nad(p)h oxidase: Association with endothelial dysfunction and clinical risk factors. Circ. Res., 2000, 86, e85-e90.
7. Heitzer, T.; Schlinzig, T.; Krohn, K.; Meinertz, T.; Munzel, T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation, 2001, 104(22), 2673-2678.
8. Lum, H.; Roebuck, K. A. Oxidant stress and endothelial cell dysfunction. Am.J. Physiol. Cell Physiol., 2001, 280(4), C719-741.
9. Ross, R. Atherosclerosis--an inflammatory disease. N. Engl. J. Med., 1999, 340(2), 115-126.
10. Guzik, T. J.; Korbut, R.; Adamek-Guzik, T. Nitric oxide and superoxide in inflammation and immune regulation. J. Physiol. Pharmacol., 2003, 54(4), 469-487.
11. Fortuno, A.; Olivan, S.; Beloqui, O.; San Jose, G.; Moreno, M. U.; Diez, J.; Zalba, G. Association of increased phagocytic nadph oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. J. Hypertens., 2004, 22(11), 2169-2175.
12. Rothe, G.; Valet, G. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2',7'-dichlorofluorescin. J. Leukoc. Biol., 1990, 47(5), 440-448.
13. Szuldrzynski, K.; Zalewski, J.; Machnik, A.;Zmudka, K. Elevated levels of 8-iso-prostaglandin f2alpha in acute coronary syndromes are associated with systemic and local platelet activation. Pol. Arch. Med. Wewne, 2009, 120(1-2), 19-24.
14. Piotrowski, W. J.; Kurmanowska, Z.; Antczak, A.; Marczak, J.; Majewski, S.; Gorski, P. Superoxide anion production by bronchoalveolar lavage cells in relation to cellular composition and lung function in sarcoidosis and chronic bronchitis. Pol. Arch. Med. Wewne, 2008, 119(12), 777-784.
15. Salonen, R. M.; Nyyssonen, K.; Kaikkonen, J.; Porkkala-Sarataho, E.; Voutilainen, S.; Rissanen, T. H.; Tuomainen, T. P.; Valkonen, V. P.; Ristonmaa, U.; Lakka, H. M.; Vanharanta, M.; Salonen, J. T.; Poulsen, H. E. Six-year effect of combined vitamin c and e supplementation on atherosclerotic progression: The antioxidant supplementation in atherosclerosis prevention (asap) study. Circulation, 2003, 107(7), 947-953.
16. Antoniades, C.; Tousoulis, D.; Tentolouris, C.; Toutouzas, P.; Stefanadis, C. Oxidative stress, antioxidant vitamins, and atherosclerosis. From basic research to clinical practice. Herz, 2003, 28(7), 628-638.
17. Heart Protection Study Collaborative Group. Mrc/bhf heart protection study of antioxidant vitamin supplementation in 20,536 highrisk individuals: A randomised placebo-controlled trial. Lancet, 2002, 360(9326), 23-33.
18. Brown, B. G.; Zhao, X. Q.; Chait, A.; Fisher, L. D.; Cheung, M. C.; Morse, J. S.; Dowdy, A. A.; Marino, E. K.; Bolson, E. L.; Alaupovic, P.; Frohlich, J.; Albers, J. J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med., 2001, 345(22), 1583-1592.
19. Ohara, Y.; Peterson, T. E.; Harrison, D. G. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest., 1993, 91(6), 2546-2551.
20. Guzik, T. J.; West, N. E. J.; Black, E.; McDonald, D.; Ratnatunga, C.; Pillai, R.; Channon, K. M. Functional effect of the c242t polymorphism in the nad(p)h oxidase p22phox subunit on vascular superoxide production in atherosclerosis. Circulation, 2000, 102(15), 1744-1747.
21. Vepa, S.; Scribner, W. M.; Parinandi, N. L.; English, D.; Garcia, J. G.; Natarajan, V. Hydrogen peroxide stimulates tyrosine phosphorylation of focal adhesion kinase in vascular endothelial cells. Am. J. Physiol., 1999, 277(1 Pt 1), L150-158.
22. Perticone, F.; Sciacqua, A.; Maio, R.; Perticone, M.; Galiano Leone, G.; Bruni, R.; Di Cello, S.; Pascale, A.; Talarico, G.; Greco, L.; Andreozzi, F.;Sesti, G. Endothelial dysfunction, adma and insulin resistance in essential hypertension. Int. J. Cardiol., 2010, 142(3), 236-241.
23. Bauersachs, J.; Schafer, A. Tetrahydrobiopterin and enos dimer/ monomer ratio--a clue to enos uncoupling in diabetes? Cardiovasc. Res., 2005, 65(4), 768-769.
24. Bourcier, T.; Sukhova, G.; Libby, P. The nuclear factor kappa-b signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem, 1997, 272(25), 15817-15824.
25. Mehrabian, M.; Allayee, H.; Wong, J.; Shi, W.; Wang, X. P.; Shaposhnik, Z.; Funk, C. D.;Lusis, A. J. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ. Res., 2002, 91(2), 120-126.
26. Dwyer, J. H.; Allayee, H.; Dwyer, K. M.; Fan, J.; Wu, H.; Mar, R.; Lusis, A. J.; Mehrabian, M. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N. Engl. J. Med., 2004, 350(1), 29-37.
27. Cyrus, T.; Witztum, J. L.; Rader, D. J.; Tangirala, R.; Fazio, S.; Linton, M. F.;Funk, C. D. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo e-deficient mice. J. Clin. Invest., 1999, 103(11), 1597-1604.
28. Berk, B. C. Novel approaches to treat oxidative stress and cardiovascular diseases. Trans. Am. Clin. Climatol. Assoc., 2007, 118, 209-214.
29. Higashi, Y.; Jitsuiki, D.; Chayama, K.; Yoshizumi, M. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases. Recent Pat. Cardiovasc. Drug Discov., 2006, 1(1), 85-93.
30. Iida, H.; Nagasaka, T.; Shindo, K.;Shiozawa, Z. Effect of the free radical scavenger edaravone on peripheral nerve ischemiareperfusion injury. Muscle Nerve., 2009, 40(4), 582-588.
31. Wen, J.; Watanabe, K.; Ma, M.; Yamaguchi, K.; Tachikawa, H.; Kodama, M.; Aizawa, Y. Edaravone inhibits jnk-c-jun pathway and restores anti-oxidative defense after ischemia-reperfusion injury in aged rats. Biol. Pharm. Bull., 2006, 29(4), 713-718.
32. Zhang, Y. M.; Wang, Y.; Liu, X. H.; Zhang, D. W. [cardioprotective effect of edaravone pharmacological postconditioning on acute myocardial ischemia/reperfusion injury: Experiment with rats]. Zhonghua Yi Xue Za Zhi, 2008, 88(36), 2558-2561.
33. Jitsuiki, D.; Higashi, Y.; Goto, C.; Kimura, M.; Noma, K.; Hara, K.; Nakagawa, K.; Oshima, T.; Chayama, K.;Yoshizumi, M. Effect of edaravone, a novel free radical scavenger, on endotheliumdependent vasodilation in smokers. Am. J. Cardiol., 2004, 94(8), 1070-1073.
34. Sliz, D.; Mamcarz, A.; Filipiak, K. J.; Siebert, J.; Naruszewicz, M. 3st-pol trial: Standards of statin use in poland in the context of the european society of cardiology guidelines. Pol. Arch. Med. Wewn, 2010, 120(9), 328-333.
35. Wassmann, S.; Laufs, U.; Muller, K.; Konkol, C.; Ahlbory, K.; Baumer, A. T.; Linz, W.; Bohm, M.; Nickenig, G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol., 2002, 22(2), 300-305.
36. Rueckschloss, U.; Galle, J.; Holtz, J.; Zerkowski, H. R.; Morawietz, H. Induction of nad(p)h oxidase by oxidized lowdensity lipoprotein in human endothelial cells: Antioxidative potential of hydroxymethylglutaryl coenzyme a reductase inhibitor therapy. Circulation, 2001, 104(15), 1767-1772.
37. Guzik, T. J.; Griendling, K. K. Nadph oxidases: Molecular understanding finally reaching the clinical level? Antioxid. Redox. Signal, 2009, 11(10), 2365-2370.
38. Guzik, T. J.; Harrison, D. G. Vascular nadph oxidases as drug targets for novel antioxidant strategies. Drug Discov. Today, 2006, 11(11-12), 524-533.
39. Rey, F. E.; Cifuentes, M. E.; Kiarash, A.; Quinn, M. T.; Pagano, P. J. Novel competitive inhibitor of nad(p)h oxidase assembly attenuates vascular o(2)(-) and systolic blood pressure in mice. Circ. Res, 2001, 89(5), 408-414.
40. Jacobson, G. M.; Dourron, H. M.; Liu, J.; Carretero, O. A.; Reddy, D. J.; Andrzejewski, T.; Pagano, P. J. Novel nad(p)h oxidase inhibitor suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery. Circ. Res, 2003, 92(6), 637-643.
41. Shi, J.; Ross, C. R.; Leto, T. L.; Blecha, F. Pr-39, a proline-rich antibacterial peptide that inhibits phagocyte nadph oxidase activity by binding to src homology 3 domains of p47 phox. Proc. Natl. Acad. Sci. USA, 1996, 93(12), 6014-6018.
42. Ikeda, Y.; Young, L. H.; Scalia, R.; Ross, C. R.; Lefer, A. M. Pr-39, a proline/arginine-rich antimicrobial peptide, exerts cardioprotective effects in myocardial ischemia-reperfusion. Cardiovasc. Res., 2001, 49(1), 69-77.
43. Stolk, J.; Hiltermann, T. J.; Dijkman, J. H.; Verhoeven, A. J. Characteristics of the inhibition of nadph oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am. J. Respir. Cell Mol. Biol., 1994, 11(1), 95-102.
44. Ghosh, M.; Wang, H. D.; McNeill, J. R. Role of oxidative stress and nitric oxide in regulation of spontaneous tone in aorta of docasalt hypertensive rats. Br. J. Pharmacol., 2004, 141(4), 562-573.
45. Lapperre, T. S.; Jimenez, L. A.; Antonicelli, F.; Drost, E. M.; Hiemstra, P. S.; Stolk, J.; MacNee, W.; Rahman, I. Apocynin increases glutathione synthesis and activates ap-1 in alveolar epithelial cells. FEBS Lett., 1999, 443(2), 235-239.
46. Diatchuk, V.; Lotan, O.; Koshkin, V.; Wikstroem, P.; Pick, E. Inhibition of nadph oxidase activation by 4-(2-aminoethyl)-benzenesulfonyl fluoride and related compounds. J. Biol. Chem., 1997, 272(20), 13292-13301.
47. Cayatte, A. J.; Rupin, A.; Oliver-Krasinski, J.; Maitland, K.; Sansilvestri-Morel, P.; Boussard, M. F.; Wierzbicki, M.; Verbeuren, T. J.; Cohen, R. A. S17834, a new inhibitor of cell adhesion and atherosclerosis that targets nadph oxidase. Arterioscler. Thromb. Vasc. Biol., 2001, 21(10), 1577-1584.
48. Heitzer, T.; Wenzel, U.; Hink, U.; Krollner, D.; Skatchkov, M.; Stahl, R. A.; MacHarzina, R.; Brasen, J. H.; Meinertz, T.; Muenzel, T. Increased nad(p)h oxidase-mediated superoxide production in renovascular hypertension: Evidence for an involvement of protein kinase c. Kidney Int., 1999, 55(1), 252-260.
49. Mollnau, H.; Wendt, M.; Szocs, K.; Lassegue, B.; Schulz, E.; Oelze, M.; Li, H.; Bodenschatz, M.; August, M.; Kleschyov, A. L.; Tsilimingas, N.; Walter, U.; Forstermann, U.; Meinertz, T.; Griendling, K.; Munzel, T. Effects of angiotensin ii infusion on the expression and function of nad(p)h oxidase and components of nitric oxide/cgmp signaling. Circ. Res., 2002, 90(4), E58-65.
50. Guzik, T.; Sadowski, J.; Kapelak, B.; Jopek, A.; Rudzinski, P.; Pillai, R.; Korbut, R.; Channon, K. Systemic regulation of vascular nad(p)h oxidase activity and nox isoform expression in human arteries and veins. Arterioscler. Thromb. Vasc. Biol., 2004, 24(9), 1614-1620.
51. Guzik, T. J.; Mussa, S.; Gastaldi, D.; Sadowski, J.; Ratnatunga, C.; Pillai, R.; Channon, K. M. Mechanisms of increased vascular superoxide production in human diabetes mellitus: Role of nad(p)h oxidase and endothelial nitric oxide synthase. Circulation, 2002, 105, 1656-1662.
52. Beckman, J. A.; Goldfine, A. B.; Gordon, M. B.; Garrett, L. A.; Creager, M. A. Inhibition of protein kinase c beta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ. Res., 2002, 90(1), 107-111.
53. Al-Awwadi, N. A.; Araiz, C.; Bornet, A.; Delbosc, S.; Cristol, J. P.; Linck, N.; Azay, J.; Teissedre, P. L.; Cros, G. Extracts enriched in different polyphenolic families normalize increased cardiac nadph oxidase expression while having differential effects on insulin resistance, hypertension, and cardiac hypertrophy in high-fructosefed rats. J. Agric. Food Chem., 2005, 53(1), 151-157.
54. Ryszawa, N.; Rudzinski, P.; Piatek, J.; Mrozek, B.; Krawiec, P.; Kosiniak-Kamysz, W.; Adamek-Guzik, T.; Sadowski, J.; Korbut, R.; Guzik, T. Different reactivity of the proximal and distal segments of the radial artery to vasoconstrictors in patients undergoing coronary artery bypass grafting. Kardiol. Pol., 2007, 65(11), 1313-1319.
55. Tsuda, M.; Iwai, M.; Li, J. M.; Li, H. S.; Min, L. J.; Ide, A.; Okumura, M.; Suzuki, J.; Mogi, M.; Suzuki, H.; Horiuchi, M. Inhibitory effects of at1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension, 2005, 45(4), 545-551.
56. Figtree, G. A.; Guzik, T.; Robinson, B. G.; Channon, K. M.; Watkins, H. Functional estrogen receptor alpha promoter polymorphism is associated with improved endothelial-dependent vasolidation. Int. J. Cardiol., 2010, 143(2), 207-208.
57. Kawczynska-Drozdz, A.; Olszanecki, R.; Jawien, J.; Brzozowski, T.; Pawlik, W. W.; Korbut, R.; Guzik, T. J. Ghrelin inhibits vascular superoxide production in spontaneously hypertensive rats. Am. J. Hypertens., 2006, 19(7), 764-767.
58. West, N. E. J.; Qian, H. S.; Guzik, T. J.; Black, E.; Cai, S.; George, S. E.; Channon, K. M. Nitric oxide synthase (nnos) gene transfer modifies venous bypass graft remodeling: Effects on vascular smooth muscle cell differentiation and superoxide production. Circulation, 2001, 104, 1526-1532.
59. Czesnikiewicz-Guzik, M.; Lorkowska, B.; Zapala, J.; Czajka, M.; Szuta, M.; Loster, B.; Guzik, T. J.; Korbut, R. Nadph oxidase and uncoupled nitric oxide synthase are major sources of reactive oxygen species in oral squamous cell carcinoma. Potential implications for immune regulation in high oxidative stress conditions. J. Physiol. Pharmacol., 2008, 59(1), 139-152.
60. Guzik, T. J.; Bzowska, M.; Kasprowicz, A.; Czerniawska-Mysik, G.; Wojcik, K.; Szmyd, D.; Adamek-Guzik, T.; Pryjma, J. Persistent skin colonization with staphylococcus aureus in atopic dermatitis: Relationship to clinical and immunological parameters. Clin. Exp. Allergy, 2005, 35(4), 448-455.
61. Guzik, T. J.; Chen, W.; Gongora, M. C.; Guzik, B.; Lob, H. E.; Mangalat, D.; Hoch, N.; Dikalov, S.; Rudzinski, P.; Kapelak, B.; Sadowski, J.; Harrison, D. G. Calcium-dependent nox5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J. Am. Coll. Cardiol., 2008, 52(22), 1803-1809.
62. Hoch, N. E.; Guzik, T. J.; Chen, W.; Deans, T.; Maalouf, S. A.; Gratze, P.; Weyand, C.; Harrison, D. G. Regulation of t-cell function by endogenously produced angiotensin ii. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2009, 296(2), R208-R216.
63. Nissen, S. E.; Tuzcu, E. M.; Libby, P.; Thompson, P. D.; Ghali, M.; Garza, D.; Berman, L.; Shi, H.; Buebendorf, E.; Topol, E. J. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The camelot study: A randomized controlled trial. JAMA, 2004, 292(18), 2217-2225.
64. Guzik, T. J.; Marvar, P. J.; Czesnikiewicz-Guzik, M.; Korbut, R. Perivascular adipose tissue as a messenger of the brain-vessel axis: Role in vascular inflammation and dysfunction. J. Physiol. Pharmacol., 2007, 58(4), 591-610.
65. Marvar, P. J.; Thabet, S. R.; Guzik, T. J.; Lob, H. E.; McCann, L. A.; Weyand, C.; Gordon, F. J.; Harrison, D. G. Central and peripheral mechanisms of t-lymphocyte activation and vascular inflammation produced by angiotensin ii-induced hypertension. Circ. Res., 2010, 107(2), 263-270.
66. Lob, H. E.; Marvar, P. J.; Guzik, T. J.; Sharma, S.; McCann, L. A.; Weyand, C.; Gordon, F. J.; Harrison, D. G. Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension, 2010, 55(2), 277-283.
67. Brenneman, A. R.; Kaufman, S. Characteristics of the hepatic phenylalanine-hydroxylating system in newborn rats. J. Biol. Chem., 1965, 240(9), 3617-3622.
68. Marletta, M. A. Nitric oxide synthase structure and mechanism. J. Biol. Chem., 1993, 268(17), 12231-12234.
69. Marletta, M. A. Nitric oxide synthase: Function and mechanism. Adv. Exp. Med. Biol., 1993, 338, 281-284.
70. Stuehr, D. J. Structure-function aspects in the nitric oxide synthases. Annu. Rev. Pharmacol. Toxicol., 1997, 37, 339-359.
71. Mayer, B.; Werner, E. R. In search of a function for tetrahydrobiopterin in the biosynthesis of nitric oxide. Naunyn. Schmiedebergs Arch. Pharmacol., 1995, 351(5), 453-463.
72. Gesierich, A.; Niroomand, F.; Tiefenbacher, C. P. Role of human gtp cyclohydrolase i and its regulatory protein in tetrahydrobiopterin metabolism. Basic Res. Cardiol., 2003, 98(2), 69-75.
73. Nichol, C. A.; Lee, C. L.; Edelstein, M. P.; Chao, J. Y.; Duch, D. S. Biosynthesis of tetrahydrobiopterin by de novo and salvage pathways in adrenal medulla extracts, mammalian cell cultures, and rat brain in vivo. Proc. Natl. Acad. Sci. USA, 1983, 80(6), 1546-1550.
74. Duch, D. S.; Lee, C. L.; Edelstein, M. P.; Nichol, C. A. Biosynthesis of tetrahydrobiopterin in the presence of dihydrofolate reductase inhibitors. Mol. Pharmacol., 1983, 24(1), 103-108.
75. Takimoto, E.; Champion, H. C.; Li, M.; Ren, S.; Rodriguez, E. R.; Tavazzi, B.; Lazzarino, G.; Paolocci, N.; Gabrielson, K. L.; Wang, Y.; Kass, D. A. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J. Clin. Invest., 2005, 115(5), 1221-1231.
76. Alp, N. J.; Mussa, S.; Khoo, J.; Cai, S.; Guzik, T.; Jefferson, A.; Goh, N.; Rockett, K. A.; Channon, K. M. Tetrahydrobiopterindependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic gtp-cyclohydrolase i overexpression. J. Clin. Invest., 2003, 112(5), 725-735.
77. Cai, S.; Alp, N. J.; McDonald, D.; Smith, I.; Kay, J.; Canevari, L.; Heales, S.; Channon, K. M. Gtp cyclohydrolase i gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: Effects on nitric oxide synthase activity, protein levels and dimerisation. Cardiovasc. Res., 2002, 55(4), 838-849.
78. Alp, N. J.; Channon, K. M. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler. Thromb. Vasc. Biol., 2004, 24(3), 413-420.
79. Pannirselvam, M.; Simon, V.; Verma, S.; Anderson, T.; Triggle, C. R. Chronic oral supplementation with sepiapterin prevents endothelial dysfunction and oxidative stress in small mesenteric arteries from diabetic (db/db) mice. Br. J. Pharmacol., 2003, 140(4), 701-706.
80. Nishimura, J. S.; Martasek, P.; McMillan, K.; Salerno, J.; Liu, Q.; Gross, S. S.;Masters, B. S. Modular structure of neuronal nitric oxide synthase: Localization of the arginine binding site and modulation by pterin. Biochem. Biophys. Res. Commun., 1995, 210(2), 288-294.
81. Farquharson, C. A.; Butler, R.; Hill, A.; Belch, J. J.; Struthers, A. D. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation, 2002, 106(2), 221-226.
82. Mebazaa, A. Current esc/esicm and accf/aha guidelines for the diagnosis and management of acute heart failure in adults--are there differences? Pol. Arch. Med. Wewne, 2008, 119(9), 569-573.
83. Freudenberger, R. S.; Schwarz, R. P., Jr.; Brown, J.; Moore, A.; Mann, D.; Givertz, M. M.; Colucci, W. S.; Hare, J. M. Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with nyha class III-IV congestive heart failure. Expert. Opin. Investig. Drugs, 2004, 13(11), 1509-1516.
84. Widder, J. D.; Guzik, T. J.; Mueller, C. F.; Clempus, R. E.; Schmidt, H. H.; Dikalov, S. I.; Griendling, K. K.; Jones, D. P.; Harrison, D. G. Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction caused by angiotensin II. Arterioscler. Thromb. Vasc. Biol., 2007, 27(4), 762-768.
85. Stocker, R.; Perrella, M. A. Heme oxygenase-1: A novel drug target for atherosclerotic diseases? Circulation, 2006, 114(20), 2178-2189.
86. Chen, Y. H.; Lin, S. J.; Lin, M. W.; Tsai, H. L.; Kuo, S. S.; Chen, J. W.; Charng, M. J.; Wu, T. C.; Chen, L. C.; Ding, Y. A.; Pan, W. H.; Jou, Y. S.; Chau, L. Y. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum. Genet., 2002, 111(1), 1-8.
87. Kaneda, H.; Ohno, M.; Taguchi, J.; Togo, M.; Hashimoto, H.; Ogasawara, K.; Aizawa, T.; Ishizaka, N.; Nagai, R. Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in japanese patients with coronary risk factors. Arterioscler. Thromb Vasc. Biol., 2002, 22(10), 1680-1685.
88. Agrawal, R. S.; Muangman, S.; Layne, M. D.; Melo, L.; Perrella, M. A.; Lee, R. T.; Zhang, L.; Lopez-Ilasaca, M.; Dzau, V. J. Preemptive gene therapy using recombinant adeno-associated virus delivery of extracellular superoxide dismutase protects heart against ischemic reperfusion injury, improves ventricular function and prolongs survival. Gene. Ther., 2004, 11(12), 962-969.
89. Brasen, J. H.; Leppanen, O.; Inkala, M.; Heikura, T.; Levin, M.; Ahrens, F.; Rutanen, J.; Pietsch, H.; Bergqvist, D.; Levonen, A. L.; Basu, S.; Zeller, T.; Kloppel, G.; Laukkanen, M. O.; Yla-Herttuala, S. Extracellular superoxide dismutase accelerates endothelial recovery and inhibits in-stent restenosis in stented atherosclerotic watanabe heritable hyperlipidemic rabbit aorta. J. Am. Coll Cardiol., 2007, 50(23), 2249-2253.
90. Laukkanen, M. O.; Kivela, A.; Rissanen, T.; Rutanen, J.; Karkkainen, M. K.; Leppanen, O.; Brasen, J. H.; Yla-Herttuala, S. Adenovirus-mediated extracellular superoxide dismutase gene therapy reduces neointima formation in balloon-denuded rabbit aorta. Circulation, 2002, 106(15), 1999-2003.
91. Li, J. M.; Shah, A. M. Endothelial cell superoxide generation: Regulation and relevance for cardiovascular pathophysiology. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2004, 287(5), R1014-R1030.
92. Li, Q.; Bolli, R.; Qiu, Y.; Tang, X. L.; Guo, Y.; French, B. A. Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction. Circulation, 2001, 103(14), 1893-1898.
93. Lund, D. D.; Gunnett, C. A.; Chu, Y.; Brooks, R. M.; Faraci, F. M.; Heistad, D. D. Gene transfer of extracellular superoxide dismutase improves relaxation of aorta after treatment with endotoxin. Am. J. Physiol. Heart. Circ. Physiol., 2004, 287(2), H805-H811.
94. Luoma, J. S.; Stralin, P.; Marklund, S. L.; Hiltunen, T. P.; Sarkioja, T.; Yla-Herttuala, S. Expression of extracellular sod and inos in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: Colocalization with epitopes characteristic of oxidized ldl and peroxynitrite-modified proteins. Arterioscler. Thromb. Vasc. Biol., 1998, 18(2), 157-167.
95. Oury, T. D.; Day, B. J.; Crapo, J. D. Extracellular superoxide dismutase: A regulator of nitric oxide bioavailability. Lab. Invest., 1996, 75(5), 617-636.
96. Abunasra, H. J.; Smolenski, R. T.; Morrison, K.; Yap, J.; Sheppard, M. N.; O'Brien, T.; Suzuki, K.; Jayakumar, J.; Yacoub, M. H. Efficacy of adenoviral gene transfer with manganese superoxide dismutase and endothelial nitric oxide synthase in reducing ischemia and reperfusion injury. Eur. J. Cardiothorac. Surg., 2001, 20(1), 153-158.
97. Chen, Z.; Siu, B.; Ho, Y. S.; Vincent, R.; Chua, C. C.; Hamdy, R. C.; Chua, B. H. Overexpression of mnsod protects against myocardial ischemia/reperfusion injury in transgenic mice. J. Mol. Cell Cardiol., 1998, 30(11), 2281-2289.
98. Zanetti, M.; Sato, J.; Jost, C. J.; Gloviczki, P.; Katusic, Z. S.; O'Brien, T. Gene transfer of manganese superoxide dismutase reverses vascular dysfunction in the absence but not in the presence of atherosclerotic plaque. Hum. Gene. Ther., 2001, 12(11), 1407-1416.
99. Wang, P.; Chen, H.; Qin, H.; Sankarapandi, S.; Becher, M. W.; Wong, P. C.; Zweier, J. L. Overexpression of human copper, zincsuperoxide dismutase (sod1) prevents postischemic injury. Proc. Natl. Acad. Sci. USA, 1998, 95(8), 4556-4560.
100. Quarck, R.; De Geest, B.; Stengel, D.; Mertens, A.; Lox, M.; Theilmeier, G.; Michiels, C.; Raes, M.; Bult, H.; Collen, D.; Van Veldhoven, P.; Ninio, E.; Holvoet, P. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein e-deficient mice. Circulation, 2001, 103(20), 2495-2500.
101. Turunen, P.; Puhakka, H.; Rutanen, J.; Hiltunen, M. O.; Heikura, T.; Gruchala, M.; Yla-Herttuala, S. Intravascular adenovirusmediated lipoprotein-associated phospholipase a2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Atherosclerosis, 2005, 179(1), 27-33.
102. Laukkanen, J.; Lehtolainen, P.; Gough, P. J.; Greaves, D. R.; Gordon, S.; Yla-Herttuala, S. Adenovirus-mediated gene transfer of a secreted form of human macrophage scavenger receptor inhibits modified low-density lipoprotein degradation and foam-cell formation in macrophages. Circulation, 2000, 101(10), 1091-1096.
103. Jalkanen, J.; Leppanen, P.; Narvanen, O.; Greaves, D. R.; Yla-Herttuala, S. Adenovirus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor (sr-ai) in ldl receptor knock-out mice. Atherosclerosis, 2003, 169(1), 95-103.
104. Zheng, J. S.; Yang, X. Q.; Lookingland, K. J.; Fink, G. D.; Hesslinger, C.; Kapatos, G.; Kovesdi, I.; Chen, A. F. Gene transfer of human guanosine 5'-triphosphate cyclohydrolase i restores vascular tetrahydrobiopterin level and endothelial function in low renin hypertension. Circulation, 2003, 108(10), 1238-1245.
105. Meininger, C. J.; Cai, S.; Parker, J. L.; Channon, K. M.; Kelly, K. A.; Becker, E. J.; Wood, M. K.; Wade, L. A.; Wu, G. Gtp cyclohydrolase i gene transfer reverses tetrahydrobiopterin deficiency and increases nitric oxide synthesis in endothelial cells and isolated vessels from diabetic rats. FASEB J., 2004, 18(15), 1900-1902.
106. Madhur, M. S.; Lob, H. E.; McCann, L. A.; Iwakura, Y.; Blinder, Y.; Guzik, T. J.; Harrison, D. G. Interleukin 17 promotes angiotensin ii-induced hypertension and vascular dysfunction. Hypertension, 2010, 55(2), 500-507.
107. Harrison, D. G.; Guzik, T. J.; Goronzy, J.; Weyand, C. Is hypertension an immunologic disease? Curr. Cardiol. Rep., 2008, 10(6), 464-469.
108. Guzik, T. J.; Harrison, D. G. Endothelial nf-kappab as a mediator of kidney damage: The missing link between systemic vascular and renal disease? Circ. Res., 2007, 101(3), 227-229.
109. Guzik, T. J.; Hoch, N. E.; Brown, K. A.; McCann, L. A.; Rahman, A.; Dikalov, S.; Goronzy, J.; Weyand, C.; Harrison, D. G. Role of the t cell in the genesis of angiotensin ii induced hypertension and vascular dysfunction. J. Exp. Med., 2007, 204(10), 2449-2460.
110. Gao, Y. J.; Takemori, K.; Su, L. Y.; An, W. S.; Lu, C.; Sharma, A. M.; Lee, R. M. Perivascular adipose tissue promotes vasoconstriction: The role of superoxide anion. Cardiovasc. Res., 2006, 71(2), 363-373.
111. Furukawa, S.; Fujita, T.; Shimabukuro, M.; Iwaki, M.; Yamada, Y.; Nakajima, Y.; Nakayama, O.; Makishima, M.; Matsuda, M.; Shimomura, I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest., 2004, 114(12), 1752-1761.
112. Cattaruzza, M.; Guzik, T. J.; Slodowski, W.; Pelvan, A.; Becker, J.; Halle, M.; Buchwald, A. B.; Channon, K. M.; Hecker, M. Shear stress insensitivity of endothelial nitric oxide synthase expression as a genetic risk factor for coronary heart disease. Circ. Res., 2004, 95(8), 841-847.
113. Guzik, T. J.; Adamek-Guzik, T.; Czerniawska-Mysik, A.; Dembinska-Kiec, A. Nitric oxide metabolite levels in children and adult patients with atopic eczema/dermatitis syndrome. Allergy, 2002, 57(9), 856.
114. Guzik, T. J.; Olszanecki, R.; Sadowski, J.; Kapelak, B.; Rudzinski, P.; Jopek, A.; Kawczynska, A.; Ryszawa, N.; Loster, J.; Jawien, J.; Czesnikiewicz-Guzik, M.; Channon, K. M.; Korbut, R. Superoxide dismutase activity and expression in human venous and arterial bypass graft vessels. J. Physiol. Pharmacol., 2005, 56(2), 313-323.
115. Guzik, T. J.; West, N. E.; Pillai, R.; Taggart, D. P.; Channon, K. M. Nitric oxide modulates superoxide release and peroxynitrite formation in human blood vessels. Hypertension, 2002, 39(6), 1088-1094.
116. Konturek, P. C.; Konturek, J. W.; Czesnikiewicz-Guzik, M.; Brzozowski, T.; Sito, E.; Konturek, P. C. Neuro-hormonal control of food intake; basic mechanisms and clinical implications. J. Physiol. Pharmacol., 2005, 56 (Suppl 6), 5-25.
117. Malecki, M. T.; Undas, A.; Cyganek, K.; Mirkiewicz-Sieradzka, B.; Wolkow, P.; Osmenda, G.; Walus-Miarka, M.; Guzik, T. J.; Sieradzki, J. Plasma asymmetric dimethylarginine (adma) is associated with retinopathy in type 2 diabetes mellitus. Diabetes Care, 2007, 30(11),2899-2901.
118. Ryszawa, N.; Kawczynska-Drozdz, A.; Pryjma, J.; Czesnikiewicz-Guzik, M.; Adamek-Guzik, T.; Naruszewicz, M.; Korbut, R.; Guzik, T. J. Effects of novel plant antioxidants on platelet superoxide production and aggregation in atherosclerosis. J. Physiol. Pharmacol., 2006, 57(4), 611-626.
119. Park, J.; Choe, S. S.; Choi, A. H.; Kim, K. H.; Yoon, M. J.; Suganami, T.; Ogawa, Y.; Kim, J. B. Increase in glucose-6-phosphate dehydrogenase in adipocytes stimulates oxidative stress and inflammatory signals. Diabetes, 2006, 55(11), 2939-2949.
120. Schonfeld, P.; Wojtczak, L. Fatty acids as modulators of the cellular production of reactive oxygen species. Free Radic. Biol. Med., 2008, 45(3), 231-241.
121. Guzik, T. J.; Mangalat, D.; Korbut, R. Adipocytokines-novel link between inflammation and vascular function? J Physiol Pharmacol, 2006, 57(4), 505-28.
122. Flechtner-Mors, M.; Jenkinson, C. P.; Alt, A.; Biesalski, H. K.; Adler, G.; Ditschuneit, H. H. Studies of phosphodiesterase effects on adipose tissue metabolism in obese subjects by the microdialysis technique. J. Physiol. Pharmacol., 2005, 56(3), 355-368.
123. Channon, K. M.; Guzik, T. J. Mechanisms of superoxide production in human blood vessels: Relationship to endothelial dysfunction, clinical and genetic risk factors. J. Physiol. Pharmacol., 2002, 53(4 Pt 1), 515-524.
124. Guzik, T. J.; Sadowski, J.; Guzik, B.; Jopek, A.; Kapelak, B.; Przybylowski, P.; Wierzbicki, K.; Korbut, R.; Harrison, D. G.; Channon, K. M. Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 2006, 26(2), 333-339.
125. Harrison, D. G.; Guzik, T. J.; Lob, H. E.; Madhur, M. S.; Marvar, P. J.; Thabet, S. R.; Vinh, A.; Weyand, C. M. Inflammation, immunity, and hypertension. Hypertension, 2011, 57(2), 132-140.
126. Vinh, A.; Chen, W.; Blinder, Y.; Weiss, D.; Taylor, W. R.; Goronzy, J. J.; Weyand, C. M.; Harrison, D. G.; Guzik, T. J. Inhibition and genetic ablation of the b7/cd28 t-cell costimulation axis prevents experimental hypertension. Circulation, 2010, 122(24), 2529-2537.
127. Harrison, D. G.; Gongora, M. C.; Guzik, T. J.; Widder, J. Oxidative stress and hypertension. J. Am. Soc. Hypertens, 2007, 1(1), 30-44.